Tamer Industries

Established in 1927, Cazeault Roofing offers roofing materials, installations and consulting services to homeowners and commercial building owners. Its Smart Choic system includes ceramic-fired shingles with ultraviolet blockers, and is held together with cores to help prevent premature cracking and splitting. Its shingles also have also have Dura Grip heat-activated adhesives that provide extra seal down protection to help prevent blow-offs. Cazeault Roofing is a certified roofing contractor, and offers GAF's weather stopper five-part roofing system. The weather stopper system offers protection against a variety of common roofing problems. The company is also certified to install Carlisle Roofing systems, and offers cedar shingle roofs as well. Cazeault Roofing is located in Orleans, Mass.

Vortex specializes in a variety of custom sheet metal fabrication procedures. It operates a more than 50,000-square-foot facility. The company has achieved ISO 9001:2000 certification. It maintains a machine shop that includes a machining center, lathe, drill presses and surface grinders. Vortex offers prototyping, stamping and wire electrical discharge machining (EDM) services. The company provides a range of mechanical and electromechanical assembly services. It offers the installation of cable assemblies, switches and fans. The company operates an engineering department that utilizes the AutoCAD software. It also provides shipping, sanding and polishing, and bending and forming services. Vortex s clients include Siemens, Analogic Corporation and Air Solutions.

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website